As most adjuvant cancer treatments are combinations of chemotherapeutic agents and/or radiotherapy, we are convinced that new EGFR-targeted agents, such as afatinib, will achieve their greatest efficacy in combination with traditional cytotoxic agents and/or radiotherapy. Here, EGFR is linked to cancer.